 The study enrolled 205 patients, of whom 204 were treated with mifamurtide intravenously at a dose of 2 mgm2 twice weekly at least 3 days apart for 12 weeks, and then weekly for an additional 24 weeks, for a total of 48 doses in 36 weeks following surgery for primary or metastatic disease. 